- Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL
- Adagene Presents Two Posters with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types
- Akamis Bio Presents Initial Data from the Ph 1b FORTRESS Study of NG-350A in MMR-Proficient Locally Advanced Rectal Cancer
- Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T
- BriaCell Presents Positive Ph 3 Quality of Life and Ph 2 Biomarker Data
- Cadonilimab Combination Demonstrates Promising Survival Benefit in Locally Advanced Pancreatic Cancer: Ph 2 COMPASSION-26 Data
- Ciltacabtagene autoleucel (Carvykti) led to a 100% MRD-negativity rate in patients with high-risk smoldering multiple myeloma in Ph 2 CAR-PRISM trial
- CytoDyn Presents New Leronlimab Data in Metastatic CRC
- D3 Bio Presents KRAS Pipeline Updates; Elisrasib (D3S-001) Shows Strong Phase 2 Efficacy Across Multiple Tumor Types
- Debiopharm presents preliminary clinical results of the MYTHIC study of zedoresertib and lunresertib in solid tumors with specific genetic alterations
- Everest Medicines Announces Positive First-in-Human Data for Personalized mRNA Cancer Vaccine EVM16
- Immunitas Presents Ph 1/2a Data Highlighting Anti-Tumor Activity of Novel Immunotherapy IMT-009
- KIMMTRAK doubles the likelihood of being alive at five years for 1L HLA-A*02:01+ patients with metastatic uveal melanoma
- Lirum Therapeutics Announces Positive LX-101 Data
- Marengo Reports Initial Ph 2 Clinical Results from Invikafusp Alfa Plus TRODELVY® and Unveils Partnered Novel IPN01203/STAR0501 STAR Program in Ph 1
- Nested Therapeutics Reports Initial Encouraging Clinical Activity and Favorable Tolerability of NST-628
- New Clinical Data for Investigational Candidate Zidesamtinib Presented
- Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies
- OBI Pharma Announces Ten Posters for GlycOBI(R) Glycan-based Site-Specific ADCs: Mono and Bi-Specific (inc. Dual payload) and Obrion ADC enabling technologies
- Phanes Therapeutics presents three clinical posters
- Pliant Therapeutics Announces Presentation of Updated Data from the Ph 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors
- Revolution Medicines to Present Updated Ph 1 Data for Zoldonrasib in Patients with Previously Treated KRAS G12D NSCLC
- Rznomics Reports Interim Clinical Data for RZ-001 in Hepatocellular Carcinoma Demonstrating Encouraging Efficacy and Favorable Safety Profile
- Sapience Therapeutics Presents First Clinical Results from Ph 2 Study of ST316 in 2L Colorectal Cancer
- Theriva™ Biologics Announces Additional Data from the VIRAGE Ph 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer
- Verismo Therapeutics’ Initial Clinical Data from STAR-101 Phase 1 Trial of SynKIR™-110 KIR-CAR Presented
- Zymeworks Presents New Ph 1 Data for ZW191